DE602004027393D1 - Tierproduktfreie medien und verfahren zur gewinnung eines botulinumtoxins - Google Patents

Tierproduktfreie medien und verfahren zur gewinnung eines botulinumtoxins

Info

Publication number
DE602004027393D1
DE602004027393D1 DE602004027393T DE602004027393T DE602004027393D1 DE 602004027393 D1 DE602004027393 D1 DE 602004027393D1 DE 602004027393 T DE602004027393 T DE 602004027393T DE 602004027393 T DE602004027393 T DE 602004027393T DE 602004027393 D1 DE602004027393 D1 DE 602004027393D1
Authority
DE
Germany
Prior art keywords
obtaining
botulinum toxin
free media
animal product
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004027393T
Other languages
English (en)
Inventor
Stephen Donovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34376493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004027393(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE602004027393D1 publication Critical patent/DE602004027393D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/842—Clostridium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE602004027393T 2003-09-25 2004-08-25 Tierproduktfreie medien und verfahren zur gewinnung eines botulinumtoxins Expired - Lifetime DE602004027393D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/672,876 US7148041B2 (en) 2003-09-25 2003-09-25 Animal product free media and processes for obtaining a botulinum toxin
PCT/US2004/027775 WO2005035749A2 (en) 2003-09-25 2004-08-25 Animal product free media and processes for obtaining a botulinum toxin

Publications (1)

Publication Number Publication Date
DE602004027393D1 true DE602004027393D1 (de) 2010-07-08

Family

ID=34376493

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027393T Expired - Lifetime DE602004027393D1 (de) 2003-09-25 2004-08-25 Tierproduktfreie medien und verfahren zur gewinnung eines botulinumtoxins

Country Status (18)

Country Link
US (4) US7148041B2 (de)
EP (2) EP2177607A1 (de)
JP (3) JP2007506427A (de)
KR (1) KR101100567B1 (de)
CN (1) CN1856569B (de)
AR (1) AR045813A1 (de)
AT (1) ATE469215T1 (de)
AU (1) AU2004280450B2 (de)
BR (1) BRPI0414722A (de)
CA (1) CA2540072A1 (de)
DE (1) DE602004027393D1 (de)
DK (1) DK1664292T3 (de)
ES (1) ES2344843T3 (de)
MX (1) MXPA06003029A (de)
NZ (1) NZ545503A (de)
PL (1) PL1664292T3 (de)
TW (1) TWI294914B (de)
WO (1) WO2005035749A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7148041B2 (en) * 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7160699B2 (en) * 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
AU2005327458B2 (en) 2005-03-03 2011-12-15 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
EP1893033B1 (de) * 2006-07-07 2008-10-22 Alpro NV Verfahren zur herstellung eines milchprodukt-analogs
KR20090120222A (ko) * 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
CA2766649C (en) 2009-06-24 2016-08-23 Charles N.S. Soparkar Zinc supplementation to increase responsiveness to metalloprotease therapy
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
EP2275527A1 (de) * 2009-07-17 2011-01-19 ActoGeniX NV Kulturmedium zur Fermentation von Bakterien welches frei von tierischen Bestandteilen ist
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
EP2672958A1 (de) 2011-02-08 2013-12-18 Halozyme, Inc. Zusammensetzung und lipidformulierung eines hyaluronan-abbauenden enzym und seine verwendung zur behandlung von benigner prostatahyperplasie
US9598685B2 (en) 2012-05-30 2017-03-21 President And Fellows Of Harvard College Engineered botulinum neurotoxin
BR102012013110A2 (pt) 2012-05-31 2014-05-27 Cristalia Prod Quimicos Farm Meio de cultura para bactérias do gênero clostridium livre de componentes de origem animal e processo para produção de sobrenadante contendo uma ou mais proteases com atividade colagenolítica e gelatinolítica
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
WO2014197837A1 (en) * 2013-06-06 2014-12-11 University Of Florida Research Foundation, Inc. Materials and methods for producing a biological toxin
CN107548402B (zh) 2015-03-26 2022-08-19 哈佛大学校长及研究员协会 工程改造的肉毒杆菌神经毒素
KR101729251B1 (ko) 2015-04-28 2017-04-21 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR101723168B1 (ko) * 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR101723167B1 (ko) * 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
PT3292135T (pt) * 2015-05-06 2022-11-15 Univ Catholique Louvain Uso de um polipéptido para efetuar a sinalização imunitária e/ou afetar a função de barreira intestinal e/ou regular o estado metabólico
US20170209553A1 (en) 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
UA127310C2 (uk) 2016-05-16 2023-07-19 Презідент Енд Феллоуз Оф Гарвард Колледж Спосіб очищення і активації ботулінічного нейротоксину
CN110072880B (zh) 2016-08-24 2025-02-18 哈佛大学校长及研究员协会 工程化肉毒杆菌神经毒素
TWI773686B (zh) 2016-09-13 2022-08-11 美商愛力根公司 非蛋白梭菌毒素組成物
KR102209159B1 (ko) 2019-03-29 2021-01-29 (주)제테마 독소의 제조방법
KR102197224B1 (ko) 2019-03-29 2020-12-31 (주)제테마 배지 조성물
US10851363B1 (en) * 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
KR102287437B1 (ko) * 2019-08-14 2021-08-09 주식회사 프로톡스 보툴리눔 독소의 제조방법
TWI854077B (zh) * 2019-12-20 2024-09-01 瑞士商葛德瑪控股公司 生產肉毒桿菌毒素的方法
TW202136286A (zh) * 2019-12-20 2021-10-01 瑞士商葛德瑪控股公司 純化肉毒桿菌毒素的方法
KR102750531B1 (ko) 2022-09-23 2025-01-09 (주)제테마 보툴리눔 독소 생산성을 증가시키는 방법
EP4615489A1 (de) 2022-11-07 2025-09-17 Allergan, Inc. Prävention von postoperativem vorhofflimmern mit einem botulinumtoxin
CH720447A2 (de) * 2023-01-20 2024-07-31 Abbvie Inc Zusammensetzungen von clostridium botulinum neurotoxin serotyp a

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401683A (en) * 1981-07-06 1983-08-30 Fmc Corporation Carbohydrate food products resistant to Clostridium botulinum and the formation of enterotoxin
US5314822A (en) 1992-10-15 1994-05-24 Merck & Co., Inc. Method of clonal growth of Streptococcus pneumoniae
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
AU2907695A (en) 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
DE69842010D1 (de) * 1997-05-28 2010-12-30 Novartis Vaccines & Diagnostic Verfahren zur Herstellung eines immunogenen Faktors von Corynebacterium diphtheriae unter Verwendung eines Kulturmediums mit Hefeextrakt als Aminosäurenquelle und ohne Proteinkomplexe tierischer Herkunft
US6171605B1 (en) 1999-07-08 2001-01-09 Color Access, Inc. Self tanning compositions containing DHA and propolis extract
US6558926B1 (en) 1999-07-16 2003-05-06 Massachusetts Institute Of Technology Method for production of tetanus toxin using media substantially free of animal products
AU1571801A (en) 1999-11-12 2001-05-30 Eli Lilly And Company Improved fermentation process
NZ520201A (en) 2000-02-08 2004-04-30 Allergan Inc Botulinum toxin pharmaceutical compositions comprising a polysaccharide
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
ATE396277T1 (de) * 2002-03-29 2008-06-15 Asahi Kasei Pharma Corp Verfahren zum nachweis einer milden beeinträchtigten glukosetoleranz oder insulin- hyposekretion
US20040235139A1 (en) 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
EP1493478B1 (de) 2003-07-02 2007-04-04 Filtertek Inc. Halterung mit mehreren Brücken
US7160699B2 (en) * 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7148041B2 (en) * 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
AU2005327458B2 (en) 2005-03-03 2011-12-15 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin

Also Published As

Publication number Publication date
TW200516142A (en) 2005-05-16
EP2177607A1 (de) 2010-04-21
CN1856569B (zh) 2010-12-01
AU2004280450B2 (en) 2009-02-05
US20050069562A1 (en) 2005-03-31
NZ545503A (en) 2009-04-30
US7445914B2 (en) 2008-11-04
JP2012070759A (ja) 2012-04-12
US20090022763A1 (en) 2009-01-22
BRPI0414722A (pt) 2006-11-21
DK1664292T3 (da) 2010-08-30
WO2005035749A2 (en) 2005-04-21
EP1664292A2 (de) 2006-06-07
ES2344843T3 (es) 2010-09-08
US20060228777A1 (en) 2006-10-12
US8008044B2 (en) 2011-08-30
WO2005035749A3 (en) 2005-06-02
JP2015051019A (ja) 2015-03-19
AR045813A1 (es) 2005-11-16
KR20060102330A (ko) 2006-09-27
TWI294914B (en) 2008-03-21
EP1664292B1 (de) 2010-05-26
CN1856569A (zh) 2006-11-01
US20060240514A1 (en) 2006-10-26
PL1664292T3 (pl) 2010-10-29
ATE469215T1 (de) 2010-06-15
CA2540072A1 (en) 2005-04-21
KR101100567B1 (ko) 2011-12-29
JP2007506427A (ja) 2007-03-22
US7189541B2 (en) 2007-03-13
AU2004280450A1 (en) 2005-04-21
MXPA06003029A (es) 2006-06-23
US7148041B2 (en) 2006-12-12

Similar Documents

Publication Publication Date Title
ATE469215T1 (de) Tierproduktfreie medien und verfahren zur gewinnung eines botulinumtoxins
DE602005019338D1 (de) Vorrichtung und Verfahren zur Informationsverarbeitung, Aufzeichnungsmedium und Programm
DE602005009169D1 (de) Vorrichtung und Verfahren zur Informationsverarbeitung, Aufzeichnungsmedium und Programm
DE602004026476D1 (de) Identifikationsmedium und verfahren zum identifizieren eines identifikationsmediums
DE602004005547D1 (de) Verfahren und System zur Überwachung eines Flüssigkeitsdurchflusses
EP1761869A4 (de) Media-paket und system und verfahren zur verwaltung eines media-pakets
DE602004023003D1 (de) Verfahren zur Spiegelung und Sicherung eines Speichersystems
EP1535278A4 (de) System und verfahren zur auswahl eines musikkanals
EP1899958A4 (de) Verfahren und vorrichtung zum dekodieren eines audiosignals
DE602004028434D1 (de) Informationsaufzeichnungsvorrichtung und Verfahren
DE602004010398D1 (de) Verfahren zur voraussage des verschleisses eines reifens und entsprechendes system
ATE410941T1 (de) Verfahren und einheit zur zubereitung eines nahrungsmittelprodukts
DE602006011665D1 (de) Verfahren und System zum Folgen eines Führungsfahrzeuges
DE602007009169D1 (de) Verfahren und System zum Einstellen eines RFID-Lesegerätes
EP1635282A4 (de) System und verfahren zur benutzung biologischer informationen, programm und aufzeichnungsmedium
DE602005009452D1 (de) Verfahren zum Erstellung eines "Data-processing-Objects" zur Geräteüberwachung
ATE468176T1 (de) Spritzvorrichtung und verfahren zur wirbelschichtgranulation
DE602004032381D1 (de) Verfahren und system zum automatisierten konfiguri
DE602005007131D1 (de) Gerät und Verfahren zur Bewegungsdetektion
DE502004005655D1 (de) Verfahren zur drehzahl überwachung eines bi-turboladers
DE602007008188D1 (de) Verfahren und System zum Einstellen eines RFID-Lesegerätes
DE502004010533D1 (de) Verfahren und System zum kontrollierten Bereitstellen eines fliessfähigen Mediums
DE602006017468D1 (de) Verfahren und Vorrichtung zur Hologrammaufzeichnung
DE602005023752D1 (de) Vorrichtung und Verfahren zur Bildverarbeitung, Aufzeichnungsmedium und Programm
DE502004010658D1 (de) FET-sensor und Verfahren zum Ansteuern eines solchen FET-sensors

Legal Events

Date Code Title Description
8363 Opposition against the patent